Drug intelligence / Profile preview

lidocaine hydrochloride gel 2%

Development stage
Approved
Lead developer
Farco-Pharma
Modality
Small Molecules
Administration
Intranasal, Topical
01

Overview

Lidocaine HCl Gel 2% (brand name: Glydo) is an approved topical local anesthetic formulation containing 2% lidocaine hydrochloride. It is a small-molecule sodium channel blocker that works by inhibiting voltage-gated sodium channels, thereby preventing ionic fluxes required for the initiation and conduction of nerve impulses and producing local anesthesia. Formulated as a sterile aqueous gel/jelly, it is indicated for the prevention and control of pain in procedures involving the male and female urethra, the topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation. In clinical trials, such as those conducted by the University of Utah, it has been evaluated for intranasal administration to perform a sphenopalatine ganglion (SPG) block to treat post-dural puncture headache (PDPH) following labor epidural placement.

Brand names
AnestaconGlydoJelidoUro-JetXylocaine Jelly
Other names
lidocaine HCl 2% gellidocaine HCl 2% jellylidocaine HCl gel 2%lidocaine HCl jelly 2%lidocaine hydrochloride 2% gellidocaine hydrochloride 2% jellylidocaine hydrochloride gel 2%lidocaine hydrochloride jelly 2%
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on lidocaine hydrochloride gel 2%.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine hydrochloride gel 2%.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call